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Abstract
Objective: To review the current literature on the effects of soy isoflavones, one class
of phyto-oestrogens, on cardiovascular diseases, osteoporosis, cancer and climacteric
symptoms.
Design: Many study designs were employed in the reports reviewed here, including
prospective human trials, observational human studies, animal experiments and
in vitro cell studies that explored the protective or preventive effects of soy
isoflavones (genistein, daidzein and glycitein alone or mixed).
Setting: Diverse settings were employed, depending on study design.
Subjects: Human subjects, mostly menopausal or postmenopausal, were included, as
were animal models and specific cell types.
Results: The findings were: (i) isoflavones plus soy protein together were needed to
obtain the highly significant beneficial results on blood lipids and arterial dimensions;
(ii) isoflavone treatments alone at high doses (relative to above) consistently
improved bone parameters in rodent ovariectomized models, but not in humans or
primates; (iii) isoflavones were not consistent in exerting positive effects regarding
the prevention or treatment of cancers of the mammary glands, uterus and colon; and
(iv) the effects of isoflavones on climacteric symptoms were not clear-cut.
Conclusions: The promise of soy isoflavones reducing chronic disease risk seems to
be non-uniform, with the most conclusive benefits occurring in the prevention of
cardiovascular diseases, but other organ systems, such as skeletal and reproductive












Phyto-oestrogenic molecules have received a great deal
of attention over the last few years because of their
potentially preventive roles against a few of today’s
most prevalent chronic diseases, namely, cardiovas-
cular disease, osteoporosis and hormone-related
cancers1,2. The particular plant molecules of interest
are isoflavones, which are found in abundance in
soybeans and their derivative foods, such as tofu, miso
and others. Of the several isoflavones that are made by
soybeans, genistein, in particular, has been experimen-
tally shown to be the most efficacious in human
subjects and animal models.
For the last several years, a concerted effort has been
mounted to identify alternatives to traditional hormone
replacement therapy (HRT). Pharmaceutical compa-
nies have been developing selective oestrogen receptor
modulators (SERMs), which ideally will provide the
beneficial effects of oestrogen replacement for bones,
cardiovascular system and cognitive function, without
adverse effects on breast and endometrial cancer. As a
result, SERMs should not require co-administration with
a progestin, which can eliminate the side effects that
some women experience with that hormone. The first
molecules of this new class of drugs to become
available are tamoxifen and raloxifene, which exhibit
many, but not all, of the qualities of an ideal HRT.
Many consumers would also prefer to avoid synthetic
molecules in favour of natural products. Soy phyto-
oestrogens, namely isoflavones, are now being inten-
sively investigated for their potential action as a SERM,
i.e. an alternative to HRT.
This review covers the effects of isoflavones,
predominantly genistein, on three common chronic
diseases plus the role of isoflavones in ameliorating the
hypo-oestrogenic symptoms of the menopause and the
early postmenopausal period. In addition, the dual
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cellular roles of isoflavones as both oestrogen agonists
and antagonists are discussed.
Isoflavones: plant molecules with
oestrogen-like properties
In the USA and in most western nations, the
consumption of soy products is quite low, probably
less than 5 g day−1 person−1. In contrast the mean
intakes in many Asian nations, for example by Japanese
men and women, may be approximately 10-fold
greater than in the USA. The intakes of the Japanese
result in the highest levels of phyto-oestrogens
measured in human subjects3.
The isoflavone content of soybeans and their
products illustrate the typical losses resulting from
processing of the original bean; losses of isoflavones
increase with each step4. Table 1 lists the isoflavone
contents of various soy products.
Isoflavones are present in a variety of food legumes.
The amounts present in a representative group of
leguminous seeds and sprouts are listed in Table 2, but
significantly higher amounts are found in soy products
(Table 1). Soy and soy products take on added
nutritional importance because they are the primary
foods, if not the only foods, that supply isoflavones in
the diets of human populations. Several reports include
the content of phyto-oestrogens in diverse beans5–8.
With the increasing availability of isoflavone-
enriched supplements and new soy-containing food
items in the marketplace, the total intake of isoflavones
in the US population, and possibly in other western
nations, will most likely rise substantially over the next
few decades. Females are the more likely consumers of
these soy-containing foods because of their belief in the
potential prevention of osteoporosis, cardiovascular
disease, hormone-dependent cancers and the reduc-
tion of symptoms associated with the menopause.
The chemical structures of the isoflavones in soy
have similarities to that of oestradiol-17b, the most
potent mammalian oestrogen (Fig. 1). Isoflavones in
soy, namely, genistein, daidzein and glycitein, have
several features in common with oestradiol-17b,
including an aromatic A ring with a hydroxyl group
substitution and a second hydroxyl group in the same
plane (Fig. 1) at a distance similar to that in oestradiol9.
Table 1 Isoflavone content of soybeans and soy products4
Daidzein Genistein
Soy food (mg 100 g−1)* (mg 100 g−1)*
Soybeans 84 111
Soybeans (roasted) 56 87
Soy flour 23 81
Tempeh 27 32
Tofu 15 16
* On a per dry weight basis.
Table 2 Isoflavone content of leguminous seeds and sprouts. Legumes were
analysed for daidzein (D), genistein (G), coumestrol (C), formonetin (F) and
biochanin A (B). Legumes that were found to have no detectable phyto-oestrogens
include green peas, fava beans and lentils
Phyto-oestrogens Phyto-oestrogen
Legume (mg 100 g−1) molecules
Seeds
Green beans: fresh, raw 0.2 F
Lima beans: dry, raw 1.5 C
Garbanzo beans 1.5 B
Kidney beans: cooked 0.4 B
Pinto beans: dry 4.2 C, B
Great northern beans: dry 0.6 B
Black eyed beans: dry 1.7 B
Green split peas: dry 7.3 D
Mung beans: dry 0.6 F
Sprouts
Clover sprouts 31.1 G, C, F, B
Fig. 1 Chemical structures of isoflavones and oestradiol-17b. Only
a small difference exists in the structures of isoflavones, such as
between genistein and daidzein (daidzein differs from genistein only
by the absence of a hydroxyl group on the A ring), but this structural
difference may greatly diminish the activity of an isoflavone, as in
the case of daidzein
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In 1996, a new form of the oestrogen receptor (ER),
ERb, was described in rodent tissues. Since that time, a
number of reports have documented the presence of
ERb in a wide variety of human and animal tissues,
including the breast. Cells have been shown to vary in
their distribution of ERa, the classic oestrogen receptor
and ERb molecules, depending on tissue. Reproductive
cells, especially those of the breast and uterus, are rich
in ERa, whereas other cells, such as in bone, have
greater amounts of ERb than ERa. This differential
distribution of the two types of oestrogen receptors and
the greater affinity of the isoflavones for ERb relative to
ERa suggest that the isoflavones have different effects
in different tissues10. Isoflavones occupy the oestrogen
receptors in cells, but occupancy time or affinity of
isoflavones for the ERa receptor is much lower than
that of oestradiol11. Of particular interest is the relative
affinity of the ERb receptor for the phyto-oestrogen
genistein, which is approximately seven times that of
ERa10. By binding to ERb, phyto-oestrogens may
have differential effects that may vary by site and
individual. It is therefore important to consider ERb in
any future experimental assessments of the effects of
phyto-oestrogens.
Most of the isoflavones in soy exist primarily as
glucose conjugates or glycones. For example, genistein
is an aglycone that results from the enzymatic cleavage
of genistin. Similarly, daidzein is an aglycone that
results from the removal of glucose from daidzin. These
enzymatic changes are thought to result from the
actions of gut bacteria. Figure 2 schematically illustrates
the conversion of the glycone, daidzin, to its aglycone,
daidzein, and its further metabolism to equol. Iso-
flavones may also be generated from precursor
molecules, such as formononetin, through the action
of gut flora (Fig. 2). Although most research has centred
on the aglycone forms of genistein and daidzein,
metabolites, such as equol, may contribute significantly
to the biological effects of the isoflavone molecules.
Equol and the other phyto-oestrogen metabolites are
excreted in significant amounts in the urine of people
who consume phyto-oestrogen-containing foods12.
Extensive gastrointestinal processing of the natural
products in food, including the removal of glycones
from the soy protein fraction and the conversion of
glycones to aglycones, must occur prior to intestinal
absorption and distribution to body tissues. The
isoflavones are fat-soluble molecules that are delivered
from the gut to the tissues via chylomicrons. In
addition, some of the metabolic products of isofla-
vones, in particular equol, may be transported in blood
weakly associated with serum proteins. Equol, and
possibly other isoflavones, are secreted by liver into
bile and they therefore can cycle as part of the
enterohepatic circulation13,14. This cycling may occur
several times over one or more days and allows a
steady-state concentration of these molecules to
develop in blood as long as the intake of soy foods
continues on a daily basis. Therefore, the enterohepatic
circulation of these molecules enhances their long-term
effects on tissues with oestrogen receptors. The caveat,
though, is that soy foods must be eaten on a daily basis
to maintain significant circulating concentrations.
Cells containing large numbers of oestrogen recep-
tors, specifically breast and uterine cells, were studied
initially in an attempt to understand better the specific
actions of isoflavones. The critical observation that
initiated experimental investigations of the isoflavones
was that female sheep became reproductively ineffi-
cient following the ingestion of fresh coumestan-rich
clover (subterranean), which led Australian scientists to
conclude that excesses of subterranean clover-rich diet
exerted adverse effects on uterine and possibly ovarian
function15.
Once absorbed and distributed to tissues of the body,
aglycone isoflavones or their metabolites have two
potential mechanisms of action at the cellular level.
One fate is that the isoflavones are taken up by passive
diffusion across the cell membrane and, via combina-
tion of the isoflavones with oestrogen receptors, they
act on nuclear DNA as weak oestrogen agonists or
antagonists. The classic action of oestrogenic isofla-
vones, using genistein as the model molecule, consists
of several steps: (i) combination with the oestrogen
receptor; (ii) dimerization of the genistein–oestrogen
receptor complex with one of several possible
molecules; (iii) activation of the oestrogen response
element in DNA; (iv) stimulation of DNA-directed
mRNA synthesis; and (v) the production of new protein
molecules specific to the tissue cell type (Fig. 3).
A second action of phyto-oestrogens on cells,
i.e. membrane protein (receptor) interactions, has
recently been proposed and remains controversial.
The isoflavones may interact with membrane proteins
(receptors) and exert effects that are expressed through
second messengers. The latter mechanism does not
involve the genome directly, and it is typically short
lived and more modulatory of existing cellular activities
than the more potent genomic effects. Nevertheless,
other steroid molecules, particularly 1,25-dihydroxy-
cholecalciferol (calcitriol), also have similar membrane
Fig. 2 Conversion of the isoflavone glycone, daidzin, to its
aglycone, daidzein, in the gut lumen
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protein interactions16,17. In this mechanism, several
possible second messengers, including kinase
enzymes, are activated and they in turn stimulate or
inhibit downstream pathways of metabolism and
protein products (Fig. 3). The duration of this effect
via a membrane protein interaction of isoflavones is
considered to be short lived and of limited efficacy,
unless the stimulating molecules are continuously
available in blood and tissue fluids bathing cells.
Cardiovascular disease
Coronary heart disease (CHD) is the leading cause of
death for postmenopausal women in westernized
societies. For more than 25 years, data have accumu-
lated suggesting that use of oestrogen replacement
therapy is associated with about a 40–50% lower risk of
CHD morbidity and mortality18. However, in spite of
this evidence for a beneficial effect in preventing
chronic diseases, only about 20% of postmenopausal
women in the USA take HRT for 5 years or more19.
The reasons for this poor use rate include fear of cancer
and adverse side effects resulting from the progestin
that is co-administered with oestrogen to prevent
increased risk of endometrial cancer.
Because of the poor use rate of traditional HRT,
considerable interest has arisen in finding alternatives
that women will be willing to take. Recently, the
results of the Heart and Estrogen/progestin Replace-
ment Study (HERS) were published in which
women who already had CHD were treated with
either combined HRT (0.625 mg Premarin þ 2.5 mg
medroxyprogesterone acetate given continuously) or
a placebo20. The combined HRT resulted in no
advantage compared to the placebo for risk of a
second coronary event through 5 years of treatment
(relative hazard, RH =0.99; 95% confidence interval, CI
=0.80–1.22). This study indicated that women who
already had developed CHD did not benefit from
this form of HRT (combined Premarin and Provera
given continuously), supporting the idea that other
forms of HRT (including different oestrogen or
progestin molecules in combination) or alternatives to
HRT should be explored. In addition, the negative
results of the HERS trial underscore the importance
of primary prevention. Soy phyto-oestrogens have
been a focus of research recently as a potential
therapy for postmenopausal women. Studies that
have focused on soy phyto-oestrogens and cardiovas-
cular disease in postmenopausal subjects are reviewed
below.
Evidence that soy protein with phyto-oestrogens
is beneficial
Human studies
Anderson et al.21 published a meta-analysis of 38
clinical studies that compared the effects of soy protein
treatment and a placebo on plasma lipids and
lipoproteins, risk factors for cardiovascular disease.
For studies to be included in this analysis, they had to
have measured plasma lipid concentrations at baseline
and used texturized soy protein or soy protein isolate
as the active treatment. These authors found a
Fig. 3 Genomic and non-genomic actions of isoflavones on cells. Isoflavones, such as genistein, may interact with nuclear oestrogen
receptors by either activating (þ) or inhibiting (−) transcription of cell-specific genes. Non-genomic effects of these phyto-oestrogen
molecules may include inhibitory effects on other molecules such as topoisomerase II and tyrosine kinase. (From Adlercreutz1, with
permission)
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9.3% reduction in total cholesterol concentrations (P
, 0.05) with soy treatment compared with the placebo
after adjustment for baseline measurements. They
also reported a significant reduction in low-density
lipoprotein (LDL) cholesterol (12.9%) and plasma
triglycerides (10.5%) with soy treatment. High-density
lipoprotein (HDL) cholesterol concentrations were not
significantly affected (2.4% increase). While these
studies included both men and women, the results
were not stratified by gender. Of interest, when the
results were stratified into quartiles by baseline total
cholesterol, those with the highest baseline measure
had the greatest reduction in LDL cholesterol (24.0%)
and the quartile with the lowest baseline total
cholesterol had the smallest reduction (7.7%). Thus,
overall, a moderate benefit of soy protein on plasma
lipids and lipoproteins was found, and among those
with the highest plasma cholesterol concentrations, a
substantial improvement was shown with soy con-
sumption. However, because the phyto-oestrogen
content of the soy used in most of these studies is not
known, it is impossible to determine what concentra-
tion is required to contribute to the improvement in
plasma lipid concentrations. One conclusion from this
analysis is that soy foods containing phyto-oestrogens
have beneficial effects on plasma lipid concentrations.
In a recent study by Crouse et al.22 the contribution
of the phyto-oestrogens to the cholesterol-lowering
properties of soy protein were investigated. This study
included 156 moderately hypercholesterolaemic men
and women (baseline LDL cholesterol >140 mg dl−1)
who were instructed to consume a low-fat, low-
cholesterol diet (National Cholesterol Education
Program Step 1 diet) for 4 weeks prior to the baseline
measurements. The subjects were then randomized
into one of five treatment groups, each of which
received a protein supplement containing 25 g of
protein. The treatment groups were: (i) casein protein;
(ii) isolated soy protein (ISP) with 3 mg phyto-
oestrogens; (iii) ISP with 27 mg phyto-oestrogens; (iv)
ISP with 37 mg phyto-oestrogens; and (v) ISP with
62 mg phyto-oestrogens. The participants continued
these treatments for 9 weeks. For the entire group, a
trend toward lower LDL cholesterol concentrations was
observed with increasing phyto-oestrogen content of
the soy protein supplements, but only the supplement
containing 62 mg of phyto-oestrogen resulted in
significantly lower LDL cholesterol concentrations
compared with the casein group (Fig. 4a). A greater
benefit in LDL cholesterol reduction was found among
the participants who had LDL cholesterol concentra-
tions above the median at baseline. In this subset of
participants, both the supplements containing 37 and
62 mg of phyto-oestrogen resulted in significantly
lower LDL cholesterol concentration compared with
the casein group. A significant dose–response trend
was found, with increasing phyto-oestrogen intake
resulting in increasingly lower LDL cholesterol con-
centrations. No significant effect of phyto-oestrogens
was demonstrated on HDL cholesterol concentrations
in this study. These data suggest that phyto-oestrogens
in a supplement containing 25 g of soy protein can
significantly lower LDL cholesterol concentrations and
that the higher the phyto-oestrogen content (up to
62 mg day−1), the better the response.
Baum et al.23 reported the results of a randomized
clinical trial that compared the effects of eating 40 g of
soy protein daily, containing either 56 or 90 mg of
phyto-oestrogens, with a casein/non-fat dry milk
placebo which had no phyto-oestrogens. This study
included 81 postmenopausal women who were
moderately hypercholesterolaemic at baseline (base-
line serum total cholesterol, 240–300 mg dl−1). Women
were instructed to follow the National Cholesterol
Education Program Step 1 diet for 2 weeks prior to the
baseline measurements and to continue this diet for the
duration of the treatment period (6 months). Both soy
Fig. 4 Effects of isolated soy protein (ISP) with varying concentra-
tions of isoflavones on plasma LDL cholesterol (mg dl−1). Data are
expressed as the difference from control group (casein or casein/
non-fat dry milk) adjusted for baseline values. (a) Study used 25 g
of protein per day in each of the groups (Crouse et al.22) (ISP3 =
3 mg isoflavones day−1; ISP27 =27 mg day−1; ISP37 =37 mg day−1;
ISP62 =62 mg day−1). (b) Study used 40 g of protein per day (Baum
et al.23) (ISP56 =56 mg isoflavones day−1; ISP90 =90 mg day−1)
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protein treatments resulted in significantly lower LDL
and VLDL cholesterol and higher HDL cholesterol
concentrations compared with the placebo, but no
difference in lipid response was found between the two
soy treatment groups (Fig. 4b).
Comparison of the data from the reports by Crouse
et al.22 and Baum et al.23 might suggest that no further
benefit on blood lipids can be attained with soy protein
containing phyto-oestrogen levels higher than approxi-
mately 60 mg day−1. It is also possible that the 40 g of
soy protein consumed by the participants in the study
by Baum et al.23 overwhelmed any additional benefit
that might have been seen with the higher phyto-
oestrogen content. However, both studies suggest that
phyto-oestrogen-containing soy protein can improve
plasma lipid and lipoprotein concentrations. The
study by Crouse et al.22 further suggests that soy
protein supplements containing low levels of phyto-
oestrogens are not as beneficial as those containing
higher amounts of these molecules.
Non-human primate studies
Additional information about the effects of soy protein
and phyto-oestrogens can be derived from two studies
in non-human primates. In the first, 85 male and 75
female cynomolgus monkeys were randomized into
one of three treatment groups being fed: (i) casein and
lactalbumin as the source of protein (control); (ii) soy
protein isolate that was alcohol-washed to remove
the phyto-oestrogens; or (iii) soy protein with the
isoflavones intact24,25. The diets were identical in com-
position for macronutrients. The amount of isoflavones
in the intact soy protein diet was approximately
equivalent to a human dose of 140 mg day−1. The
isoflavone-containing soy diet significantly lowered
LDL and VLDL cholesterol compared with the control
group (about 35%) and increased HDL cholesterol
(about 50%). The isoflavone-devoid soy diet resulted in
only a slight reduction (about 8%) that was not
significantly different from the control group, but
significantly increased HDL cholesterol concentrations
(about 20%). Coronary artery atherosclerosis measure-
ments were done in 11 animals from each diet group
and the cross-sectional area of the arterial lesions were
largest in the control group (0.13 mm2), smallest in
the soy with isoflavones group (0.02 mm2) and
intermediate in the isoflavone-devoid soy group
(0.06 mm2). These data suggest that the soy isoflavones
contribute greatly to the regulation of plasma lipid
concentrations and atherosclerosis.
In the second study surgically postmenopausal
monkeys were fed diets containing either: (i) alcohol-
washed, phyto-oestrogen-devoid soy protein isolate
(n =56); (ii) phyto-oestrogen-intact soy protein isolate
(n =59) with a phyto-oestrogen amount equivalent to a
dose for women of 120 mg day−1; or (iii) isoflavone-
devoid soy to which Premarin (conjugated equine
oestrogens) (n =63) was added to approximate a
woman’s dose of 0.625 mg day−1 26–28. In Fig. 5 the
effects of the soy phyto-oestrogens and traditional
oestrogen therapy on plasma lipid concentrations are
compared26. While both treatments lowered LDL and
VLDL cholesterol, soy phyto-oestrogen administration
resulted in significantly higher HDL cholesterol and
significantly lower plasma triglycerides compared to
traditional oestrogen therapy.
In addition, the effects of these two treatments on
atherosclerosis have been reported27,28, and the soy
isoflavones (approximately equivalent to a dose of
120 mg day−1 for women) appear to be equal to
conjugated equine oestrogens (equivalent to a dose
of 0.625 mg day−1 for women) in preventing athero-
sclerotic lesion development at some arterial sites (e.g.
the internal carotid arteries) and less efficient at other
sites (e.g. the common iliac artery). No explanation
currently exists for the site-specific differences in
atheroprotection of soy protein containing isoflavones.
Differences in ERa and ERb concentrations in various
tissues and differential susceptibility of these sites to
plasma lipid risk factors or direct effects of isoflavones
on the arterial wall may be other explanations.
The above study in non-human primates27,28 was the
first to compare directly the effects of traditional HRT
and soy phyto-oestrogens. The conclusion that can be
made from this study is that soy phyto-oestrogens
compare favourably with traditional oestrogen therapy
in their effects on cardiovascular disease and its risk
factors, but more studies are needed to confirm these
findings.
Lack of effect of purified isoflavones
While abundant evidence exists that soy phyto-
oestrogens, when fed in soy protein, have beneficial
effects on the cardiovascular system and risk factors,
Fig. 5 Effects of treatment with soy phyto-oestrogens (SPE) or
conjugated oestrogens (CEE) on cardiovascular risk factors and
cardiovascular disease. Data are expressed as per cent difference
from soy-fed control group (Anthony et al.107)
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two recent studies in humans suggest that the purified
isoflavones do not have the same effects. In a crossover
study by Nestel et al.29 peri- and postmenopausal
women (n =21) were treated with 80 mg isoflavones in
a tablet or a placebo pill for 5-week periods. They
found the isoflavone pills had no effects on plasma
lipid concentrations, although they did find a beneficial
effect on systemic arterial compliance (a measure of
elasticity of arteries). In a report by Hodgson et al.30,
dosing with a purified isoflavone tablet (55 mg day−1) in
a parallel arm, placebo-controlled study of 8 weeks’
duration had no effect on LDL or HDL cholesterol
concentrations in a group of men and women (n =60
per group).
Data from a study in non-human primates add
further support to the lack of effect of purified
isoflavones on plasma lipids. In a study by Greaves
et al.31, surgically postmenopausal monkeys (n =20 per
group) were fed for 12 weeks with either: (i) a
moderately atherogenic diet that had either casein
and lactalbumin as the source of protein (C/L); (ii) the
C/L diet with purified isoflavones added (C/LþIso); or
(iii) unextracted soy protein (Soy(þ)). The isoflavone
content of the C/LþIso and Soy(þ) diets were
equivalent. The addition of purified isoflavones to the
C/L-based diet (C/LþIso) had no beneficial effects on
plasma lipid/lipoprotein concentrations compared
with the control group (C/L-based diet without iso-
flavones). In contrast, the isoflavone-containing soy
protein-based diet (Soy(þ)) reduced total cholesterol
and LDL cholesterol, and increased HDL cholesterol.
These studies suggest that the isoflavones might
require the presence of soy protein in order to
beneficially affect plasma lipids. However, the finding
of a beneficial effect of the purified isoflavone pills on
systemic arterial compliance suggests that the purified
isoflavone pills may have some biological effects29.
Potential mechanisms
The evidence that soy with its phyto-oestrogens has a
beneficial effect on cardiovascular disease seems
convincing, and it appears that at least a portion of
this benefit is modulated by effects on plasma lipids
and lipoprotein concentrations. However, beneficial
effects of soy with its phyto-oestrogens, and genistein
in particular, on vascular reactivity, an indicator of
vascular function, have also been reported32. Another
potential benefit of the phyto-oestrogens, which has
been shown in vitro, is the prevention of lipoprotein
oxidation33,34, which may blunt atherosclerosis since
oxidized LDL particles are considered more athero-
genic35. Phyto-oestrogens may also have direct effects
on the artery wall and the cells involved in the
promotion and progression of atherosclerosis. Genis-
tein has been shown, in vitro, to inhibit the migration
and proliferation of smooth muscle cells36–38, to inhibit
platelet activation39,40 and aggregation41,42, and to
reduce platelet serotonin uptake43. Each of these
processes has the capability to inhibit atherosclerosis
initiation and progression.
Summary
Little doubt remains that soy with its phyto-oestrogens
has beneficial effects on cardiovascular disease and its
risk factors. A number of biological processes that may
play a role in this protection include beneficial effects
on plasma lipids and lipoproteins, improved vascular
function, and possibly favourable effects on platelets
and smooth muscle cells, cells that are important in
atherosclerosis initiation and progression. An inter-
vention incorporating soy with its phyto-oestrogens
in a western-type diet that can favourably impact
on cardiovascular disease morbidity and mortality
(e.g. stroke, myocardial infarction) has not yet been
undertaken.
Questions remain regarding dose and form of the
phyto-oestrogens to maximize the benefits and mini-
mize any potential risks. However, incorporation of soy
with its phyto-oestrogens into a western diet may prove
to be an important means of reducing cardiovascular
disease and may have additional benefits for other
chronic diseases.
Osteoporosis
The increase in skeletal fragility with ageing and the
increase in bone fractures that result because of
osteoporosis are public health concerns of enormous
magnitude as the population ages, especially as more
postmenopausal women are surviving to their 80s
and 90s. A primary clinical preventive strategy has
previously employed oestrogen replacement therapy
or HRT, but the recently introduced SERMs may
provide benefits to bone (and cardiovascular tissues)
without adverse effects on reproductive tissues (i.e.
cancer) as shown for oestrogens. The available
experimental data on the effects of isoflavones (i.e.
phyto-oestrogens) on bone suggest that these mole-
cules, especially soy-derived genistein, may actually be
naturally occurring SERMs44.
Rodent studies
The effects of isoflavones on the skeletal tissue of
experimental animals and humans have been found to
be mixed, although the rodent studies have been highly
consistent. The published reports are briefly reviewed
in this section. Several rodent models have been
examined, but little information is available for other
species, such as the primate45. Most of the rodent
experiments have employed ovariectomized (OVX)
animals to demonstrate the effects of soy isoflavones,
especially preparations that contain mixtures of
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genistein, daidzein and glycitein. Effects of isoflavones
on bone have been compared with those resulting from
similar treatment with oestrogens. Experiments using
the OVX adult female rat model have suggested
increased bone mineral density at one or more sites
was the primary outcome.
Studies from three different laboratories using OVX
rats have shown that treatment with the isoflavones
present in soy, either unpurified46, partially purified47
or purified48 (as genistein) exerted significant improve-
ment in bone mass and approximately the same per
cent retention, which may approach the gain from
treatment with replacement doses of oestradiol (Fig. 6).
The age and body weights of the rats in these three
different studies were similar, and the duration of
treatment ranged from 14 days47 to 30 days46,48. All
three of the studies incorporated the phyto-oestrogen-
containing preparation into the diet; however, the
doses used are difficult to compare. The phyto-
oestrogen content was not determined in the soy
protein isolate in the Arjmandi et al.46 study, and the
phyto-oestrogen preparation used by Anderson et al.47
was only partially purified.
Although the skeletal benefits of the isoflavones
were comparable to those of oestrogens, the dose of
isoflavones was approximately 100–1000-fold greater
than that of oestrogens (oestradiol-17b or conjugated
oestrogens). An additional benefit of the isoflavone
treatment compared with oestrogens was the lack of
any major effect of isoflavones on uterine weight.
In these experiments, the isoflavone preparation
appeared to act like a SERM because of the positive
effects on bone without any obvious effects on the
uterus, but further research is needed to establish that
isoflavones are really SERMs.
Although the results from Blair et al.48 suggest that
co-administration with soy protein is not required to
show bone-conserving effects of soy isoflavones in the
OVX rodent model, the effects of a range of doses
have not been determined. Blair et al.48 used purified
genistein at a single high dose. Only the study by
Anderson et al.47 used more than one dose, and they
reported that the lowest dose was the most effective,
with less effect at the two higher doses, i.e. a biphasic
response.
Human studies
Only a few reports on the skeletal effects of genistein or
of a genistein-rich isoflavone preparation on human
subjects have been published, and in these studies
bone mineral density at several skeletal sites or the
whole body was the primary outcome. Additional
publications on effects of isoflavones on bone mineral
density are anticipated in the next few years. One study
using a soy protein isolate containing 56 or 90 mg
phyto-oestrogens showed that older postmenopausal
women responded to the higher, but not the lower,
dosage with significantly improved lumbar verte-
bral bone mineral density (Fig. 7)49.
In vitro studies
In studies of isolated osteoblast-like cells in culture in
which the media are changed frequently, the con-
tinuous dosing of cells with an isoflavone is easy to
undertake, whereas in animal or human models it is
less certain that sufficiently high blood concentrations
can be maintained over long enough periods (e.g.
weeks to months) to have a significant impact on bone
cells. For this reason, isolated cell studies provide an
advantage because the cells are continuously bathed
with an isoflavone, much like the maintenance of a
uniform concentration of isoflavones in the blood
because of the enterohepatic circulation. The critical
element is to provide isoflavones in the culture
media at all times at a dose or doses sufficient to
exert a threshold response. Our studies with isolated
Fig. 6 Effects of (a) soy protein, (b) purified soy extract and (c)
genistein on bone mass in ovariectomized (OVX) rats. (Data from
Arjmandi et al.46, Anderson et al.47 and Blair et al.48)
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osteoblast-like MC3T3-E1 cells, treated with genistein
between days 2 and 4 in culture, then incubated for a
total of 12 days, suggest that genistein inhibits the
synthesis and secretion of IL-6, an interleukin known to
stimulate the activity of osteoclasts in bone (X. Chen
et al., unpublished data, 1999). This inhibitory effect of
genistein on IL-6 is similar to the inhibition of IL-6
following treatment of these cells with oestradiol
(Fig. 8). The significance of these data is that genistein
acts very much like oestrogens in inhibiting the
resorptive activities of osteoclasts.
An alternative mechanism for decreased osteoclastic
bone resorption by genistein is a direct effect via
inhibition of tyrosine kinase activity in osteoclasts. Blair
et al.48 reported that genistein, at doses achievable in
the circulation, can significantly decrease the amount of
bone degraded by isolated chicken osteoclasts in vitro.
Either a direct or indirect effect of genistein or other
phyto-oestrogens to decrease osteoclastic bone resorp-
tion in the absence of normal levels of circulating
oestrogens would be a potential benefit.
The potential for phyto-oestrogens to prevent loss of
bone mass has been demonstrated in experimental
rodent models, but convincing data have been more
difficult to obtain from primate and human studies. It is
possible that the few primate and human investigations
published thus far may either have used doses that
were too low or the duration of treatment may have
been too brief. The results of other studies are being
awaited.
Cancer
Demographic and epidemiological evidence for
anticancer effects
Asian women have a relatively lower risk of breast,
endometrial and colonic cancer, compared with
western women50–52. The risk of breast cancer increases
in Asian immigrants to the USA53 and in urban
subpopulations within Japan54, suggesting that envir-
onmental factors are responsible for the difference.
Asian diets typically contain less fat and a higher
proportion of vegetables, including soy products, when
compared with western diets. Among the seven case–
control studies of soy intake and breast cancer risk
published to date, there is more evidence for breast
cancer protection by soy phyto-oestrogens in pre-
menopausal women than in postmenopausal women
(Fig. 9)55–61. Therefore, there may be context-depen-
dent effects of soy phyto-oestrogens on cancer risk,
depending on life stage and/or hormonal status.
Only one epidemiological study of endometrial
Fig. 8 In vitro cell studies of osteoblasts (MC3T3-E1) showing the
inhibition of IL-6 production by the cells in a similar manner to that
found for oestradiol. IL-6 is a known stimulator of osteoclastic
resorption, and these data demonstrate that genistein acts on these
cells in a very similar way to oestradiol (X Chen et al., unpublished
data)
Fig. 7 Effects of purified soy extract on lumbar bone mineral density (BMD) in elderly women after almost 6 months of treatment. (Adapted
from Potter et al.49)
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cancer and soy phyto-oestrogen intake has been
conducted to date. In this case–control study, women
in the highest versus the lowest quartile of soy intake
had a relative risk of 0.46 (95% CI 0.26–0.83) for the
development of endometrial cancer62, i.e. about a 50%
lower risk of endometrial cancer among the quartile
with the highest intake of soy.
Epidemiological studies of colonic cancer consist of
demographic observations similar to those made for
breast and endometrial carcinoma50 and relatively few
case–control studies. Greater intakes of vegetables,
including soybeans, are associated with lower risk of
colon cancer63,64, but the contribution of phyto-
oestrogens per se to this effect has not been clearly
isolated. The mechanisms by which soy phyto-
oestrogens might diminish colon cancer risk is unclear
since consumption of soy milk decreased circulating
oestradiol in women in one study65, while in another
the use of HRT was inversely correlated with colon
cancer66.
Animal studies
Approximately two-thirds of the more than two dozen
rodent studies have shown a protective effect of soy or
soy phyto-oestrogens against chemically-induced
mammary neoplasms67. Neonatal exposure to the soy
phyto-oestrogen, genistein, has produced a mammary
cancer-protective effect later in life68; a similar finding
has been made for exposure at puberty69. However, it is
worthwhile to note that soy phyto-oestrogens promote
the growth of human MCF-7 breast cancer cells in vitro
and that the growth of these cancerous cells injected
into nude mice has been promoted by administration of
dietary genistein70. Because of the paucity of endo-
metrial cancer models, animal studies have been
limited to uterotrophic assays or intermediate marker
assays.
Soy phyto-oestrogens clearly are not mammotrophic
or uterotrophic in macaques, when given at doses
similar to those attained in the Asian diet. Recent work
has shown that the oestrogenic or anti-oestrogenic
effect of soy phyto-oestrogens is dependent on
hormonal context. In monkeys given a hormone-
replacement dose of oestrogen, dietary soy supple-
mentation decreased oestrogen-induced proliferation
in both mammary and uterine tissues and, therefore,
could potentially decrease the cancer-promoting effect
of oestrogen71. Other studies in rats have indicated
that the effects of dietary oestrogens and oestrogen-
replacement therapy are interactive and dose-depen-
dent, such that soy phyto-oestrogens may increase
breast cell proliferation at low doses of oestrogens, but
may decrease breast cell proliferation when given in
combination with high doses of oestrogens (JM Cline,
unpublished data).
Animal studies of colorectal cancer and soy have
produced conflicting results. Induction of atypical
colonic crypts by azoxymethane has been inhibited
by soy intake in rodent models72,73; however, the
development of colonic tumours induced by the same
carcinogen has been promoted by soy intake74. The
development of colonic neoplasms in the transgenic
ApcMin mouse (bearing the murine homologue of the
familial polyposis gene) was not inhibited by soy
isoflavones given in a ‘western-type’ diet75. Treatment
with other specific components of soy, for example the
Bowman–Birk inhibitor76 and soybean saponins73, has
resulted in diminished tumorigenesis.
Anticancer mechanisms
There are a number of mechanistic reasons why soy
phyto-oestrogens may be cancer-protective, including
a variety of antiproliferative effects, modulation of
steroid hormone-metabolizing enzymes and binding
Fig. 9 Case–control studies of soy intake or soy isoflavone excretion and breast cancer risk56,61. The distribution of risk estimates in studies
including premenopausal women suggests a relatively greater protection of soy phyto-oestrogens against premenopausal women than
postmenopausal women55–59,61
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proteins, induction of apoptosis (programmed cell
death) and possible antiangiogenic effects.
The most extensively studied isoflavone is genistein.
Genistein binds with approximately 0.4% of the affinity
of oestradiol to the oestrogen receptor11. Several
investigators have shown that in the absence of
oestrogen, isoflavones have weakly oestrogenic effects,
whereas in the presence of oestrogen, they may exert
an antagonistic effect77,78. This suggests a competitive,
oestrogen receptor-mediated mechanism. However,
the generality of this phenomenon has not been
shown for all tissues, and particularly not for the
mammary gland. It may be that the weak oestrogenicity
of genistein has little to do with its breast cancer-
protective effects79. At higher doses (>10 mmol l−1),
genistein has antiproliferative effects in MCF-7 breast
cancer cells without respect to their oestrogen receptor
positivity80. This effect is, therefore, presumably not
dependent on the receptor, and may be mediated by
genistein’s potent inhibition of tyrosine kinase activity
(see Fig. 3)81. Genistein is also an inhibitor of DNA
topoisomerase82, which may be an integral part of its
differentiation-inducing properties. It is also an anti-
oxidant83, and induces apoptosis in breast cancer cell
lines in vitro84. Furthermore, genistein also has
antiproliferative and antiangiogenic effects on vascular
endothelial cells in vitro85, leading to the hypothesis
that its antiangiogenic properties may be responsible
for the relatively indolent nature of breast carcinomas
in Asian women. Genistein also induces expression of
the inhibitory growth factor, transforming growth factor
(TGF) b, which diminishes epithelial cell proliferation
in the breast86.
When considering the cancer-protective effects of
soy, it is important not to have a preconceived notion of
the compounds responsible for the benefits. Also
present in soy products are a number of compounds
other than genistein and other isoflavones that may
exert anticancer effects, such as saponins87, phytic
acid88 and protease inhibitors89. The degree to which
they might contribute to cancer prevention, either




In addition to ERb, splicing variants of the oestrogen
receptor are variably expressed in both tumours and
normal tissues90. These variants may be constitutively
active even in the absence of oestrogen, or may
have dominant negative activity (i.e. they may bind
oestrogen but fail to activate the oestrogen response
element). In the normal mammary gland, such variants
may account for interindividual differences in breast
cancer susceptibility, and may contribute to unex-
pected responses to chemopreventive agents and
hormonal treatments. In tumours, such oestrogen
receptor variants may account for the failure of some
immunohistochemically oestrogen receptor-positive
tumours to respond to hormonal therapy. For example,
the presence of the exon-3 deleted variant is associated
with tumours that are oestrogen-receptor positive but
progesterone-receptor negative91.
Potential cancer risk associated with
phyto-oestrogens
Some recent in vitro and in vivo studies suggest that the
growth of normal and neoplastic breast epithelium is
promoted by phyto-oestrogens70,92,93. The widely used
MCF-7 breast cancer cell line responds with prolifera-
tion to doses of genistein in the low micromolar range
both in vitro and in vivo70. These data may indicate risk
of tumour promotion in women with inapparent or
recurrent breast cancer; however, it is worthwhile to
note that MCF-7 cells are cancerous and transformed.
Animal inoculation studies with these cells, therefore,
address promotion but not the initiation step in
carcinogenesis. Important differences exist between
MCF-7 and normal breast epithelial cells. For example,
MCF-7 cells excrete less of the inhibitory factor TGF-b
than non-epithelial cells and respond with proliferation
to genistein, while normal human mammary epithelial
cells respond by growing less86. The basis for this
difference between normal and neoplastic cells may lie
in the paracrine regulation of the breast. For example,
in normal breast epithelial cells, sex steroid receptor
expression and proliferation hardly ever occur in the
same cells, implying paracrine signalling or temporal
separation; in contrast, in breast tumours, the receptors
and proliferation occur together94. With respect to non-
neoplastic breast tissue, some concern is raised by the
work of McMichael-Phillips et al.93, who found that
short-term (2 weeks) treatment with dietary soy protein
isolate (60 mg day−1) may increase proliferation of
breast epithelial cells in women. This finding, too,
could represent a cancer-promoting effect. Thus, while
the weight of the data from epidemiological and
anticarcinogenic studies suggests a cancer-protective
effect, data also exist that support the opposite
conclusion.
Summary
The rate differentials, migratory data and time trends of
cancer risk in human populations indicate that an
unknown epigenetic factor in the western lifestyle
predisposes women to cancers of the breast, endome-
trium and colon. The contribution of vegetable intake
to lower cancer risk is clear; however, the degree to
which one can attribute the anticancer effect to soy
phyto-oestrogens is still uncertain. Part of this problem
is the result of recent developments in our knowledge
of oestrogen receptor function; ‘oestrogenicity’ can no
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longer be easily defined. Not all women are likely to
be affected equally by consumption of soy phyto-
oestrogens, because of interindividual differences in
phyto-oestrogen metabolism95 and potentially because
of differences in oestrogen receptor types between
women. The benefit of soy phyto-oestrogens is clearer
for dietary exposures early in life and for premeno-
pausal women. However, because the in vitro data
suggest that normal breast cells and cancerous breast
cells respond differently to phyto-oestrogens, the
benefit for older women and breast cancer survivors
remains to be determined. Understanding the effects of
soy phyto-oestrogens will require (i) careful considera-
tion of the hormonal status and phyto-oestrogen-
metabolizing status of women participating in soy
prevention trials; (ii) further exploration of the relevant
paracrine mediators in the tissues of interest; and (iii)
quantification of the effects of different oestrogen
receptors, such as ERb, for which soy phyto-oestrogens
may have particular affinity.
Climacteric symptoms
Women in the Pacific Rim report fewer symptoms
related to hypo-oestrogenism during the climacteric
than western women96,97. Soy-containing foods are
much more prevalent in East Asian diets than in
western diets98. Soy is also a rich source of several
oestrogenic isoflavanoid compounds (e.g. genistein and
daidzein)98. These observations suggest that the iso-
flavones in soy may have oestrogen agonist properties.
Genistein suppresses gonadotropin-releasing hormone
(GnRH)-induced leutinizing hormone (LH) secretion
in OVX rats, and also prevents progesterone-induced
suppression of LH in OVX rats99–101. A diet enriched
with 60 g of soy protein (45 mg isoflavones) per day
prolonged the follicular phase of the menstrual cycle
and suppressed the mid-cycle GnRH-induced LH and
follicle-stimulating hormone surges in premenopausal
women102. These experimental observations suggest
that the isoflavones in soy may have oestrogen
antagonist properties. Since more than 70% of western
women experience hot flushes in the climacteric, and
since soy may represent a dietary alternative to more
traditional postmenopausal HRT, it is important to
consider the impact of soy, as an isoflavone-rich food,
on hot flushes as a measure of their effect on climacteric
symptoms in general. Table 3 summarizes the pub-
lished trials that have examined the effect of isoflavone
supplementation on hot flushes.
The four studies, all randomized and blinded, offer
interesting contrasts. The Murkies et al. study utilized a
phyto-oestrogen-poor control treatment, wheat flour,
and the subjects were instructed to finish the prescribed
treatment over the course of the entire day103. The
Brzezinski et al. trial utilized an unsupplemented,
isoflavone-poor diet as its control, and instructed the
subjects randomized to a ‘phyto-oestrogen rich’ diet to
consume an appropriate amount of isoflavone-rich
foods during the day104. The Albertazzi et al. trial
utilized a casein (isoflavone-free) supplement as the
control105, and the Washburn et al. trial utilized a
carbohydrate supplement (isoflavone free) as the
control106. Except for the Washburn trial, the soy
supplements were administered at least twice daily.
Washburn et al.106 found no effect on either hot flush
frequency or severity in his once daily treatment
regimen (34 mg isoflavones), but did find reduced hot
flush severity when the dose was administered at two
time points instead of one (17 mg BID isoflavones). The
Murkies et al.103 trial reported improvement in both
hot flush and menopausal symptom scores in both
treatment groups compared to baseline, but the
improvements were not different between treatments.
Brzezinski et al.104 did not compare the effects of
treatment between groups, although it appears that
improvements in total menopausal symptoms score
and hot flushes were similar in both the isoflavone-
supplemented and control diet groups. However, the
vaginal dryness score appeared to be more improved in
the isoflavone-supplemented group compared with the
control diet group104. The trial by Albertazzi et al.105
found significantly greater reductions in hot flush
frequency and severity among isoflavone users.
Several inferences may be taken from these trials.
The ‘bioavailability’ of isoflavones in the isolated soy
protein preparations may be better than that found in
whole foods. Increasing the frequency of dosing may
improve symptom relief. While a dose as low as 10 g of
isolated soy protein twice daily decreased the
frequency of hot flushes in a single study106, it appears
that a dose of at least 20 g twice daily is necessary to
reduce hot flush severity. All treatments included were
a combination of both the isoflavones and either the
Table 3 Summary of published trials on the effect of isoflavone supplementation on hot flushes
Protein Isoflavone Treatment Hot flush severity Hot flush frequency
Study (g day−1) (mg day−1) duration (weeks) (% change) (% change)
Murkies et al.103 45 74 12 NR NE
Brzezinski et al.104 NR NR 12 NR NE
Albertazzi et al.105 40 76 12 NR −15
Washburn et al.106 20 (10 BID) 34 (17 BID) 12 −22 NE
BID, twice daily; NE, no effect; NR, not reported.
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whole foods they are found in or isolated soy protein.
No published reports were found regarding the
efficacy, if any, of preparations containing only the
isoflavones themselves (exclusive of soy protein).
Finally, while the effect of isoflavones on menopausal
symptoms is both real and clinically relevant for both
hot flush severity and frequency, the effect does not
appear to be as great as that of traditional pharmaco-
logical oestrogen replacement therapy.
Public health implications
In terms of both health promotion and chronic disease
prevention, the potential public health impact of soy
consumption on a daily basis could be important.
Research findings suggest that reductions in cardiovas-
cular disease, osteoporosis and perhaps reproductive
and other cancers may be possible with routine
consumption of soy products containing isoflavones.
The challenge will be getting consumers, especially
those in the western nations of the world, to modify
their eating habits by including generous amounts of
soy and its derivative foods in their diets on a daily
basis. Nutrition education will be important in
developing behavioural changes in the selection and
use of these soy-containing foods.
Growing evidence from several sources indicates
that the potential exists for selective activity of dietary
phytochemicals, depending on the oestrogen receptor
subtype, which may vary between different individuals
and in different tissues. Therefore, these molecules may
be naturally occurring SERMs. Although evidence
continues to emerge that phytochemicals decrease the
incidence of breast cancer, many observations are only
phenomenological. Much work needs to be done to
explore basic mechanisms. Regardless of whether the
aggregate effect of phyto-oestrogens diminishes, or
even raises, breast cancer risk, widespread consump-
tion of phytochemicals in the human diet (and via
supplements) makes it imperative that we understand
their effects, particularly as they relate to differing
developmental and functional stages of breast epithelia.
To suggest that soy-derived isoflavones can replace
oestrogen replacement therapy or HRT in the treatment
of postmenopausal women seems premature, but for
those women who refuse HRT therapy because of a
family history of breast cancer or for other medical or
personal reasons, soy with isoflavones may offer an
alternative treatment with some benefits for chronic
disease risk.
Conclusions
A few major conclusions can be drawn from the
established effects of isoflavones from soy and soy
products on tissue structures and functions.
1. The isoflavone effects appear to be tissue specific,
i.e. in some tissues these soy-derived molecules act like
oestrogens (agonists), whereas in others they may act
as oestrogen antagonists. In their actions as agonists or
antagonists in different tissues, isoflavones appear to
behave as SERMs, a class of drugs with similar agonistic
and antagonistic properties.
2. Dosages of isoflavones need to be quite high, in the
60–100 mg day−1 range, in order to exert their
beneficial effects on cells of different types present in
tissues throughout the body. A threshold for efficacy on
cardiovascular tissue and bone seems to be greater than
60 mg day−1 while effects on climacteric symptoms may
be seen at lower doses, i.e. approximately 20 mg day−1.
3. Administration of isolated soy isoflavones, i.e. pure
genistein, has not proved to be as effective in
promoting beneficial effects on cardiovascular tissues
as the same dose of isoflavones administered together
with soy protein. This result suggests that a diet
containing soy and its phyto-oestrogens may be more
likely to promote these health benefits than isoflavone
supplements alone. Bone studies in rodent models,
however, yielded similar results whether proteins
accompanied the isoflavone or not.
4. Isoflavone concentrations in blood appear to be
optimized and stabilized by the continuous recycling of
these molecules via the enterohepatic circulation.
These mechanisms ensure that concentrations of
phyto-oestrogens are maintained at sufficiently high
levels throughout fairly long periods, much like the
elevation of oestrogens during parts of the menstrual
cycle, during pregnancy and with oestrogen replace-
ment therapy.
5. Specific benefits of soy-containing isoflavones have
been documented for reducing blood lipids and
relaxing arterial walls, but beneficial effects have
been more difficult to establish for bone health
during the menopause despite some studies with
favourable results. The effects of isoflavones on the
prevention of specific cancers remains highly uncer-
tain. The minimum dosages of isoflavones at which
benefits are obtained may vary from tissue to tissue,
and the role of isoflavone consumption as part of soy-
derived foods or together with isolated soy protein
remains to be determined.
6. Little concern exists about excessive doses of
isoflavones from consumption of soy foods. How-
ever, the introduction of purified isoflavone supple-
ments to consumers increases the possibility that
toxic or adverse health effects could occur with high
dosages.
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32 Honoré EK, Williams JK, Anthony MS, Clarkson TB. Soy
isoflavones enhance vascular reactivity in atherosclerotic
female macaques. Fertil. Steril. 1997; 67: 148–54.
33 Hodgson JM, Croft KD, Puddey IB, Mori TA, Beillin LJ.
Soybean isoflavonoids and their metabolic products inhibit
in vitro lipoprotein oxidation in serum. J. Nutr. Biochem.
1996; 7: 664–9.
34 Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell
GP, Rice-Evans CA. Antioxidant activity of phytoestrogenic
isoflavones. Free Radic. Res. 1997; 26: 63–70.
35 Witztum JL, Steinberg D. Role of oxidized low density
lipoprotein in atherogenesis. J. Clin. Invest. 1991; 88: 1785–
92.
36 Fujio Y, Yamada F, Takahashi K, Shibata N. Responses of
smooth muscle cells to platelet-derived growth factor are
inhibited by herbimycin-A tyrosine kinase inhibitor.
Biochem. Biophys. Res. Commun. 1993; 195: 79–83.
37 Shimokado K, Yokota T, Umezawa K, Sasaguri T, Ogata J.
Protein tyrosine kinase inhibitors inhibit chemotaxis of
vascular smooth muscle cells. Arterioscler. Thromb. 1994;
14: 973–981.
Downloaded from https://www.cambridge.org/core. 05 Feb 2021 at 14:08:25, subject to the Cambridge Core terms of use.
503Health potential of soy isoflavones for menopausal women
38 Shimokado K, Umezawa K, Ogata J. Tyrosine kinase
inhibitors inhibit multiple steps of the cell cycle of vascular
smooth muscle cells. Exp. Cell. Res. 1995; 220: 266–73.
39 Kuruvilla A, Putcha G, Poulos E, Shearer WT. Tyrosine
phosphorylation of phospholipase C concomitant with its
activation by platelet-activating factor in a human B cell line.
J. Immunol. 1993; 151: 637–48.
40 Murphy CT, Kellie S, Westwick J. Tyrosine-kinase activity in
rabbit platelets stimulated with platelet-activating factor. The
effect of inhibiting tyrosine kinase with genistein on platelet-
signal-molecule elevation and functional responses. Eur. J.
Biochem. 1993; 216: 639–51.
41 Asahi M, Yanagi S, Ohta S, et al. Thrombin-induced human
platelet aggregation is inhibited by protein-tyrosine kinase
inhibitors, ST638 and genistein. FEBS Lett. 1992; 309: 10–14.
42 McNicol A. The effects of genistein on platelet function are
due to thromboxane receptor antagonism rather than
inhibition of tyrosine kinase. Prostaglandins Leukot.
Essent. Fatty Acids 1993; 48: 379–84.
43 Helmeste DM, Tang SW. Tyrosine kinase inhibitors regulate
serotonin uptake in platelets. Eur. J. Pharmacol. 1995; 280:
R5–7.
44 Anderson JJB, Garner SC. Phytoestrogens and bone. In:
Adlercreutz HL, ed. Balliere’s Clinical Endocrinology and
Metabolism, Vol. 12. London: Ballière Tyndall, 1998; 1–16.
45 Lees C, Ginn TA. Soy protein isolate diet does not prevent
increased cortical bone turnover in ovariectomized maca-
ques. Calcif. Tissue Int. 1998; 62: 557–8.
46 Arjmandi BH, Alekel L, Hollis BW, et al. Dietary soybean
protein prevents bone loss in an ovariectomized rat model
of osteoporosis. J. Nutr. 1996; 126: 161–7.
47 Anderson JJB, Ambrose WW, Garner SC. Biphasic effects of
genistein on bone tissue in the ovariectomized, lactating rat
model. Proc. Soc. Exp. Biol. Med. 1998; 217: 345–50.
48 Blair HC, Jordan SE, Peterson TG, Barnes S. Variable effects
of tyrosine kinase inhibitors on avian oseoclastic activity and
reduction of bone loss in ovariectomized rats. J. Cell.
Biochem. 1996; 61: 629–37.
49 Potter SM, Baum JA, Teng H, Stillman RJ, Erdman JW Jr. Soy
protein and isoflavones: their effects on blood lipids and
bone density in postmenopausal women. Am. J. Clin. Nutr.
1998; 68 (Suppl. 6): S1375–9.
50 Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J.
Cancer Incidence in Five Continents. IARC Scientific
Publication No. 120. Lyon: International Agency for
Research on Cancer, 1992.
51 Wynder EL, Fujita Y, Harris RE, Hirayama T, Hiyama T.
Comparative epidemiology of cancer between the United
States and Japan: a second look. Cancer 1991; 67: 746–63.
52 Yu H, Harris RE, Gao YT, Gao R, Wynder EL. Comparative
epidemiology of cancers of the colon, rectum, prostate and
breast in Shanghai, China versus the United States. Int. J.
Epidemiol. 1991; 20: 76–81.
53 Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns
and breast cancer risk in Asian–American women. J. Natl.
Cancer Inst. 1993; 85: 1819–27.
54 Kato I, Tominaga S, Kuroishi T. Relationship between
westernization of dietary habits and mortality from breast
and ovarian cancers in Japan. Jpn. J. Cancer Res. 1987; 78:
349–57.
55 Hirose K, Tajima K, Hamajima N, et al. A large-scale,
hospital-based case–control study of risk factors of breast
cancer according to menopausal status. Jpn. J. Cancer Res.
1995; 86: 146–54.
56 Ingram D, Sanders K, Kolybaba M, Lopez D. Case–control
study of phyto-oestrogens and breast cancer. Lancet 1997;
350: 990–4.
57 Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary
effects on breast-cancer risk in Singapore. Lancet 1991; 337:
1197–200.
58 Witte JS, Ursin G, Siemiatycki J, Thompson WD, Paganini-
Hill A, Haile RW. Diet and premenopausal bilateral breast
cancer: a case–control study. Breast Cancer Res. Treat. 1997;
42: 243–51.
59 Wu AH, Ziegler RG, Horn-Ross PL, et al. Tofu and risk of
breast cancer in Asian–Americans. Cancer Epidemiol. Bio-
mark. Prevent. 1996; 5: 901–6.
60 Yuan JM, Wang QS, Ross RK, Henderson BE, Yu MC. Diet
and breast cancer in Shanghai and Tianjin, China. Br. J.
Cancer 1995; 71: 1353–8.
61 Zheng W, Dai Q, Custer LJ, Shu X, Wen W, Jin F, Franke AA.
Urinary excretion of isoflavonoids and the risk of
breast cancer. Cancer Epidemiol. Biomark. Prevent. 1999;
8: 35–40.
62 Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH,
Kolonel LN. Association of soy and fiber consumption with
the risk of endometrial cancer. Am. J. Epidemiol. 1997; 146:
294–306.
63 Le Marchand L, Hankin JH, Wilkens LR, Kolonel LN, Englyst
HN, Lyu LC. Dietary fiber and colorectal cancer risk.
Epidemiology 1997; 8: 658–65.
64 Witte JS, Longnecker MP, Bird CL, Lee ER, Frankl HD, Haile
RW. Relation of vegetable, fruit, and grain consumption to
colorectal adenomatous polyps. Am. J. Epidemiol 1996; 144:
1015–25.
65 Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of soya
consumption for one month on steroid hormones in
premenopausal women: implications for breast cancer risk
reduction. Cancer Epidemiol. Biomark. Prevent. 1996; 5:
63–70.
66 Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S.
Hormone replacement therapy, reproductive history, and
colon cancer: a multicenter, case–control study in the
United States. Cancer Causes Control 1997; 8: 146–58.
67 Barnes S. The chemopreventive properties of soy isoflavo-
noids in animal models of breast cancer. Breast Cancer Res.
Treat. 1997; 46: 169–79.
68 Lamartiniere CA, Moore J, Holland M, Barnes S. Neonatal
genistein chemo prevents mammary cancer. Proc. Soc. Exp.
Biol. Med. 1995; 208: 120–3.
69 Lamartiniere CA, Murrill WB, Manzolillo PA, et al. Genistein
alters the ontogeny of mammary gland development and
protects against chemically-induced mammary cancer in
rats. Proc. Soc. Exp. Biol. Med. 1998; 217: 358–64.
70 Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic
effects of genistein on the growth of estrogen receptor-
positive human breast cancer (MCF-7) cells in vitro and in
vivo. Cancer Res. 1998; 58: 3833–8.
71 Foth D, Cline JM. Effects of mammalian and plant estrogens
on mammary glands and uteri of macaques. Am. J. Clin.
Nutr. 1998; 68 (Suppl.): S1413–17.
72 Thiagarajan DG, Bennink MR, Bourquin LD, Kavas FA.
Prevention of precancerous colonic lesions in rats by soy
flakes, soy flour, genistein, and calcium. Am. J. Clin. Nutr.
1998; 68 (Suppl.): S1394–9.
73 Koratkar R, Rao AV. Effect of soya bean saponins on
azoxymethane-induced preneoplastic lesions in the colon of
mice. Nutr. Cancer 1997; 27: 206–9.
74 Rao CV, Wang CX, Simi B, et al. Enhancement of
experimental colon cancer by genistein. Cancer Res. 1997;
57: 3717–22.
75 Sorensen IK, Kristiansen E, Mortensen A, et al. The effect of
soy isoflavones on the development of intestinal neoplasia
in ApcMin mouse. Cancer Lett 1998; 130: 217–25.
76 Weed HG, McGandy RB, Kennedy AR. Protection against
dimethylhydrazine-induced adenomatous tumors of the
mouse colon by the dietary addition of an extract of
soybeans containing the Bowman–Birk protease inhibitor.
Carcinogenesis 1985; 6: 1239–41.
77 Folman Y, Pope GS. The interaction in the immature mouse
Downloaded from https://www.cambridge.org/core. 05 Feb 2021 at 14:08:25, subject to the Cambridge Core terms of use.
504 JJB Anderson et al.
of potent oestrogens with coumestrol, genistein and other
utero-vaginotrophic compounds of low potency. J. Endo-
crinol. 1966; 34: 215–25.
78 Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and
cancer risk: a review of the in vitro and in vivo data. Nutr.
Cancer 1994; 21: 113–31.
79 Barnes S, Peterson TG. Biochemical targets of the isoflavone
genistein in tumor cell lines. Proc. Soc. Exp. Biol. Med. 1995;
208: 103–8.
80 Peterson G, Barnes S. Genistein inhibition of the growth of
human breast cancer cells: independence from estrogen
receptors and the multi-drug resistance gene. Biochem.
Biophys. Res. Commun. 1991; 179: 661–7.
81 Akiyama T, Ishida JSN, Nakagawa S, et al. Genistein, a
specific inhibitor of tyrosine-specific protein kinases. J. Biol.
Chem. 1987; 262: 5592–5.
82 Constantinou A, Huberman E. Genistein as an inducer of
tumor cell differentiation: possible mechanisms of action.
Proc. Soc. Exp. Biol. Med. 1995; 208: 109–15.
83 Wei H, Bowen R, Cai Q, Barnes S, Wang Y. Antioxidant and
antipromotional effects of the soybean isoflavone genistein.
Proc. Soc. Exp. Biol. Med. 1995; 208: 124–30.
84 Kiguchi K, Glesne D, Chubb CH, Fujiki H, Huberman E.
Differential induction of apoptosis in human breast tumor
cells by okadaic acid and related inhibitors of protein
phosphatases 1 and 2A. Cell Growth Differ. 1994; 5: 995–1004.
85 Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-
derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad.
Sci. USA 1993; 90: 2690–4.
86 Sathyamoorthy N, Gilsdorf JS, Wang TT. Differential effect of
genistein on transforming growth factor beta 1 expression in
normal and malignant mammary epithelial cells. Anticancer
Res. 1998; 18: 2449–53.
87 Rao AV, Sung MK. Saponins as anticarcinogens. J. Nutr. 1995;
125 (Suppl. 3): S717–24.
88 Shamsuddin AM. Inositol phosphates have novel anticancer
function. J. Nutr. 1995; 125 (Suppl. 3): S725–32.
89 Kennedy AR. The evidence for soybean products as cancer
preventive agents. J. Nutr. 1995; 125 (Suppl. 3): S733–43.
90 Miksicek RJ, Lei Y, Wang Y. Exon skipping gives rise to
alternatively spliced forms of the estrogen receptor in breast
tumor cells. Breast Cancer Res. Treat. 1993; 26: 163–74.
91 Zhang QX, Hilsenbeck SG, Fuqua SA, Borg A. Multiple
splicing variants of the estrogen receptor are present in
individual human breast tumors. J. Steroid Biochem. Mol.
Biol. 1996; 59: 251–60.
92 Makela S, Davis VL, Tally WC, et al. Dietary estrogens act
through estrogen receptor mediated processes and show no
antiestrogenicity in cultured breast cancer cells. Environ.
Health Perspect. 1994; 102: 572–8.
93 McMichael-Phillips DF, Harding C, Morton M, et al. Effects of
soy-protein supplementation on epithelial proliferation in
the histologically normal human breast. Am. J. Clin. Nutr.
1998; 68 (Suppl.): S1431–5.
94 Clarke RB, Howell A, Potten CS, Anderson E. Dissociation
between steroid receptor expression and cell proliferation in
the human breast. Cancer Res. 1997; 57: 4987–91.
95 Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA.
The variable metabolic response to dietary isoflavones in
humans. Proc. Soc. Exp. Biol. Med. 1995; 208: 40–3.
96 Boulet MJ, Odden BJ, Lehert P, Vemer HM, Visser A.
Climacteric and menopause in seven southeast Asian
countries. Maturitas 1994; 19: 157–76.
97 Notelovitz M. Estrogen replacement therapy indications,
contraindications, and agent selection. Am. J. Obstet.
Gynecol. 1989; 161: 8–17.
98 Adlercreutz H. Western diets and western diseases: some
hormonal and biochemical mechanisms and associations.
Scand. J. Clin. Lab. Invest. 1990; 50 (Suppl.): 3–23.
99 Hughes CL. Effects of phytoestrogens on GnRH-induced
luteinizing hormone secretion in ovariectomized rats.
Reprod. Toxicol. 1988; 1: 179–81.
100 Hughes CL, Kaldas RS, Weisinger AS, McCants CE, Basham
KB. Acute and subacute effects of naturally occurring
estrogens on luteinizing hormone secretion in the ovar-
iectomized rat: 1. Reprod. Toxicol. 1991; 5: 127–32.
101 Hughes CL, Chakinali MM, Reece SG, Miller RN, Schomberg
DW, Basham KB. Acute and subacute effects of naturally
occurring estrogens on luteinizing hormone secretion in the
ovariectomized rat: 2. Reprod. Toxicol. 1991; 5: 133–7.
102 Cassidy A, Bingham S, Setchell KDR. Biological effects of a
diet of soy protein rich in isoflavones on the menstrual
cycle of premenopausal women. Am. J. Clin. Nutr. 1994; 60:
333–40.
103 Murkies AL, Lombard C, Strauss BJG, Wikcox G, Burger HG,
Morton MS. Dietary flour supplementation decreases post-
menopausal hot flushes: effect of soy and wheat. Maturitas
1995; 21: 189–95.
104 Brzezinski A, Adlercreutz H, Shaoul R, Shmueli A, Reosler A,
Schenker JG. Phytoestrogen-rich diet for postmenopausal
women. Fifth World Congress on Gynecology, Endocrinol-
ogy, Barcelona, Spain, 1996. Abstract FC.H-02.
105 Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De
Aloysio D. The effect of dietary soy supplementation on hot
flushes. Obstet. Gynecol. 1998; 91: 6–11.
106 Washburn SA, Burke GL, Morgan TG, Anthony MS. Effect of
soy protein supplementation on serum lipoproteins, blood
pressure, and menopausal symptoms in perimenopausal
women. Menopause 1999; 6: 7–13.
107 Anthony MS, Clarkson TB, Hughes CL. Plant and mamma-
lian estrogen effects on plasma lipids of female monkeys.
Circulation 1994; 90: I-235 (abstract).
Downloaded from https://www.cambridge.org/core. 05 Feb 2021 at 14:08:25, subject to the Cambridge Core terms of use.
